Cargando…

Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment

Spinal cord injury (SCI) is an injurious process that begins with immediate physical damage to the spinal cord and associated tissues during an acute traumatic event. However, the tissue damage expands in both intensity and volume in the subsequent subacute phase. At this stage, numerous events exac...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinelli, Filippo, Pizzetti, Fabio, Veneruso, Valeria, Petillo, Emilia, Raghunath, Michael, Perale, Giuseppe, Veglianese, Pietro, Rossi, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313204/
https://www.ncbi.nlm.nih.gov/pubmed/35884981
http://dx.doi.org/10.3390/biomedicines10071673
_version_ 1784754022259884032
author Pinelli, Filippo
Pizzetti, Fabio
Veneruso, Valeria
Petillo, Emilia
Raghunath, Michael
Perale, Giuseppe
Veglianese, Pietro
Rossi, Filippo
author_facet Pinelli, Filippo
Pizzetti, Fabio
Veneruso, Valeria
Petillo, Emilia
Raghunath, Michael
Perale, Giuseppe
Veglianese, Pietro
Rossi, Filippo
author_sort Pinelli, Filippo
collection PubMed
description Spinal cord injury (SCI) is an injurious process that begins with immediate physical damage to the spinal cord and associated tissues during an acute traumatic event. However, the tissue damage expands in both intensity and volume in the subsequent subacute phase. At this stage, numerous events exacerbate the pathological condition, and therein lies the main cause of post-traumatic neural degeneration, which then ends with the chronic phase. In recent years, therapeutic interventions addressing different neurodegenerative mechanisms have been proposed, but have met with limited success when translated into clinical settings. The underlying reasons for this are that the pathogenesis of SCI is a continued multifactorial disease, and the treatment of only one factor is not sufficient to curb neural degeneration and resulting paralysis. Recent advances have led to the development of biomaterials aiming to promote in situ combinatorial strategies using drugs/biomolecules to achieve a maximized multitarget approach. This review provides an overview of single and combinatorial regenerative-factor-based treatments as well as potential delivery options to treat SCIs.
format Online
Article
Text
id pubmed-9313204
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93132042022-07-26 Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment Pinelli, Filippo Pizzetti, Fabio Veneruso, Valeria Petillo, Emilia Raghunath, Michael Perale, Giuseppe Veglianese, Pietro Rossi, Filippo Biomedicines Review Spinal cord injury (SCI) is an injurious process that begins with immediate physical damage to the spinal cord and associated tissues during an acute traumatic event. However, the tissue damage expands in both intensity and volume in the subsequent subacute phase. At this stage, numerous events exacerbate the pathological condition, and therein lies the main cause of post-traumatic neural degeneration, which then ends with the chronic phase. In recent years, therapeutic interventions addressing different neurodegenerative mechanisms have been proposed, but have met with limited success when translated into clinical settings. The underlying reasons for this are that the pathogenesis of SCI is a continued multifactorial disease, and the treatment of only one factor is not sufficient to curb neural degeneration and resulting paralysis. Recent advances have led to the development of biomaterials aiming to promote in situ combinatorial strategies using drugs/biomolecules to achieve a maximized multitarget approach. This review provides an overview of single and combinatorial regenerative-factor-based treatments as well as potential delivery options to treat SCIs. MDPI 2022-07-12 /pmc/articles/PMC9313204/ /pubmed/35884981 http://dx.doi.org/10.3390/biomedicines10071673 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pinelli, Filippo
Pizzetti, Fabio
Veneruso, Valeria
Petillo, Emilia
Raghunath, Michael
Perale, Giuseppe
Veglianese, Pietro
Rossi, Filippo
Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment
title Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment
title_full Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment
title_fullStr Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment
title_full_unstemmed Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment
title_short Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment
title_sort biomaterial-mediated factor delivery for spinal cord injury treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313204/
https://www.ncbi.nlm.nih.gov/pubmed/35884981
http://dx.doi.org/10.3390/biomedicines10071673
work_keys_str_mv AT pinellifilippo biomaterialmediatedfactordeliveryforspinalcordinjurytreatment
AT pizzettifabio biomaterialmediatedfactordeliveryforspinalcordinjurytreatment
AT venerusovaleria biomaterialmediatedfactordeliveryforspinalcordinjurytreatment
AT petilloemilia biomaterialmediatedfactordeliveryforspinalcordinjurytreatment
AT raghunathmichael biomaterialmediatedfactordeliveryforspinalcordinjurytreatment
AT peralegiuseppe biomaterialmediatedfactordeliveryforspinalcordinjurytreatment
AT veglianesepietro biomaterialmediatedfactordeliveryforspinalcordinjurytreatment
AT rossifilippo biomaterialmediatedfactordeliveryforspinalcordinjurytreatment